

# Michael H Meel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1790557/publications.pdf>

Version: 2024-02-01

17  
papers

321  
citations

840776

11  
h-index

1058476

14  
g-index

18  
all docs

18  
docs citations

18  
times ranked

601  
citing authors

#	ARTICLE	IF	CITATIONS
1	AURKA and PLK1 inhibition selectively and synergistically block cell cycle progression in diffuse midline glioma. <i>IScience</i> , 2022, 25, 104398.	4.1	10
2	Defining tumor-associated vascular heterogeneity in pediatric high-grade and diffuse midline gliomas. <i>Acta Neuropathologica Communications</i> , 2021, 9, 142.	5.2	18
3	MEK/MELK inhibition and blood-brain barrier deficiencies in atypical teratoid/rhabdoid tumors. <i>Neuro-Oncology</i> , 2020, 22, 58-69.	1.2	21
4	Combined Therapy of AXL and HDAC Inhibition Reverses Mesenchymal Transition in Diffuse Intrinsic Pontine Glioma. <i>Clinical Cancer Research</i> , 2020, 26, 3319-3332.	7.0	44
5	Development of transient radioresistance during fractionated irradiation in vitro. <i>Radiotherapy and Oncology</i> , 2020, 148, 107-114.	0.6	12
6	Celastrol-induced degradation of FANCD2 sensitizes pediatric high-grade gliomas to the DNA-crosslinking agent carboplatin. <i>EBioMedicine</i> , 2019, 50, 81-92.	6.1	23
7	International experience in the development of patient-derived xenograft models of diffuse intrinsic pontine glioma. <i>Journal of Neuro-Oncology</i> , 2019, 141, 253-263.	2.9	30
8	Multiregional Tumor Drug-Uptake Imaging by PET and Microvascular Morphology in End-Stage Diffuse Intrinsic Pontine Glioma. <i>Journal of Nuclear Medicine</i> , 2018, 59, 612-615.	5.0	24
9	Signaling pathways and mesenchymal transition in pediatric high-grade glioma. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 871-887.	5.4	44
10	ATRT-19. PRECLINICAL EFFICACY OF COMBINED INHIBITION OF MEK AND MELK IN ATYPICAL TERATOID/RHABDOID TUMORS. <i>Neuro-Oncology</i> , 2018, 20, i31-i31.	1.2	0
11	DIPG-05. PRECLINICAL EFFICACY OF MELK INHIBITION IN DIFFUSE INTRINSIC PONTINE GLIOMA. <i>Neuro-Oncology</i> , 2018, 20, i49-i50.	1.2	0
12	MELK Inhibition in Diffuse Intrinsic Pontine Glioma. <i>Clinical Cancer Research</i> , 2018, 24, 5645-5657.	7.0	30
13	An efficient method for the transduction of primary pediatric glioma neurospheres. <i>MethodsX</i> , 2018, 5, 173-183.	1.6	12
14	DIPG-04. INHIBITION OF AXL SENSITIZES DIFFUSE INTRINSIC PONTINE GLIOMA TO CYTOTOXIC THERAPIES. <i>Neuro-Oncology</i> , 2018, 20, i49-i49.	1.2	0
15	Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma. <i>Journal of Neurosurgery: Pediatrics</i> , 2017, 19, 518-530.	1.3	23
16	Culture methods of diffuse intrinsic pontine glioma cells determine response to targeted therapies. <i>Experimental Cell Research</i> , 2017, 360, 397-403.	2.6	26
17	DIPG-15. EFFECTIVE PRECLINICAL TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA BY MELK INHIBITION. <i>Neuro-Oncology</i> , 2017, 19, iv7-iv8.	1.2	0